{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Salisbury",
      "state": "MD",
      "country": "United States",
      "classification": "Class III",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "82280",
      "recalling_firm": "Jubilant Cadista Pharmaceuticals, Inc.",
      "address_1": "207 Kiley Dr",
      "address_2": "N/A",
      "postal_code": "21801-2249",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Product was distributed to one customer who may have further distributed the product.",
      "recall_number": "D-0519-2019",
      "product_description": "BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150 mg, a) 30 count (NDC 59746- 758-30) & b) 90 count (NDC 59746-758-90) bottles, Rx only, Manufactured b Jubilant Generis Ltd, Roorkee, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD",
      "product_quantity": "a) 3,072 bottles; b) 2,688 bottles",
      "reason_for_recall": "Failed Dissolution Specifications; 9-monthstability timepoint",
      "recall_initiation_date": "20190228",
      "center_classification_date": "20190306",
      "termination_date": "20200305",
      "report_date": "20190313",
      "code_info": "a) BR117002C, exp. date 11/2019;   b) BR117003B and BR117004B, exp. date 11/2019"
    }
  ]
}